OBJECTIVE: To present oncological results with intermittent androgen deprivation (IAD) in a single center. METHODS: Between 1992 and 2008, 566 patients with prostate cancer (PC) were selected for a non-randomized study of IAD. Two hundred and eighteen patients had biochemical recurrence (BCR) after local treatment for PC and 348 patients had micro- or macro-metastatic disease. On-treatment period (ONTP) consisted of three-monthly injections of gonadatropin-releasing hormone (GnRH) agonist combined with daily oral androgen receptor antagonist. Off-treatment period (OFTP) was indicated when prostate-specific antigen (PSA) was <4 ng/ml. Criteria for resumption of hormonal therapy were PSA >20 ng/ml or clinical symptoms. Cancer specific survival curves were computed according to the Kaplan-Meier method. RESULTS: Median follow-up was 81 months (12-230). Median age was 74.7 years (52-92). Median Gleason score at diagnosis was 7 (3-9). Median initial PSA was 17 ng/ml (0.4-433). Cycle duration decreased progressively from 23 months for the 1st cycle to 10 months at 12th cycle. The number of patients who became hormone resistant was 182 (32%). Median cancer specific survival probability for the series is 12 (10.8-infinity) years. No previous treatment group showed a higher cancer specific survival probability (log rank test, CI 95%, P = 0.003) versus BCR group. Multivariate analysis of cancer specific survival demonstrates age, initial Gleason score and initial PSA level as significant factors affecting mortality (P < 0.05). CONCLUSIONS: Intermittent androgen deprivation is an acceptable treatment in different stages of PC. Duration of cycle decreased progressively during therapy. Age, Gleason score and PSA are factors predicting mortality.
OBJECTIVE: To present oncological results with intermittent androgen deprivation (IAD) in a single center. METHODS: Between 1992 and 2008, 566 patients with prostate cancer (PC) were selected for a non-randomized study of IAD. Two hundred and eighteen patients had biochemical recurrence (BCR) after local treatment for PC and 348 patients had micro- or macro-metastatic disease. On-treatment period (ONTP) consisted of three-monthly injections of gonadatropin-releasing hormone (GnRH) agonist combined with daily oral androgen receptor antagonist. Off-treatment period (OFTP) was indicated when prostate-specific antigen (PSA) was <4 ng/ml. Criteria for resumption of hormonal therapy were PSA >20 ng/ml or clinical symptoms. Cancer specific survival curves were computed according to the Kaplan-Meier method. RESULTS: Median follow-up was 81 months (12-230). Median age was 74.7 years (52-92). Median Gleason score at diagnosis was 7 (3-9). Median initial PSA was 17 ng/ml (0.4-433). Cycle duration decreased progressively from 23 months for the 1st cycle to 10 months at 12th cycle. The number of patients who became hormone resistant was 182 (32%). Median cancer specific survival probability for the series is 12 (10.8-infinity) years. No previous treatment group showed a higher cancer specific survival probability (log rank test, CI 95%, P = 0.003) versus BCR group. Multivariate analysis of cancer specific survival demonstrates age, initial Gleason score and initial PSA level as significant factors affecting mortality (P < 0.05). CONCLUSIONS: Intermittent androgen deprivation is an acceptable treatment in different stages of PC. Duration of cycle decreased progressively during therapy. Age, Gleason score and PSA are factors predicting mortality.
Authors: K Akakura; N Bruchovsky; P S Rennie; A J Coldman; S L Goldenberg; M Tenniswood; K Fox Journal: J Steroid Biochem Mol Biol Date: 1996-12 Impact factor: 4.292
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: R A Janknegt; C C Abbou; R Bartoletti; L Bernstein-Hahn; B Bracken; J M Brisset; F C Da Silva; G Chisholm; E D Crawford; F M Debruyne Journal: J Urol Date: 1993-01 Impact factor: 7.450
Authors: Emmanuel S Antonarakis; Yongmei Chen; Sally I Elsamanoudi; Stephen A Brassell; Mario V Da Rocha; Mario A Eisenberger; David G McLeod Journal: BJU Int Date: 2010-11-23 Impact factor: 5.588
Authors: Emmanuel S Antonarakis; Marianna L Zahurak; Jianqing Lin; Daniel Keizman; Michael A Carducci; Mario A Eisenberger Journal: Cancer Date: 2012-03-15 Impact factor: 6.860
Authors: Daniel Keizman; Peng Huang; Emmanuel S Antonarakis; Victoria Sinibaldi; Michael A Carducci; Samuel Denmeade; Jenny J Kim; Janet Walczak; Mario A Eisenberger Journal: Prostate Date: 2011-03-22 Impact factor: 4.104